Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Net Cash Flow (2016 - 2025)

Regenxbio (RGNX) has 12 years of Net Cash Flow data on record, last reported at -$24.3 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 2777.23% year-over-year to -$24.3 million; the TTM value through Dec 2025 reached -$23.1 million, down 200.24%, while the annual FY2025 figure was -$23.1 million, 200.24% down from the prior year.
  • Net Cash Flow reached -$24.3 million in Q4 2025 per RGNX's latest filing, down from -$20.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $117.5 million in Q4 2021 and bottomed at -$153.3 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$15.2 million, with a median of -$21.2 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: crashed 45476.7% in 2021, then soared 392.07% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $117.5 million in 2021, then plummeted by 118.37% to -$21.6 million in 2022, then rose by 13.17% to -$18.7 million in 2023, then surged by 104.85% to $909000.0 in 2024, then tumbled by 2777.23% to -$24.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$24.3 million in Q4 2025, -$20.8 million in Q3 2025, and -$50.5 million in Q2 2025.